Detail akcie Transcode Thera Rg online

Business Summary: TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Transcode Therapeutics Inc revenues was not reported. Net loss increased 96% to $21.2M. Higher net loss reflects Research and development increase of 31% to $7.9M (expense), Interest income decrease from $1K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$1424.10 to -$81.11.